Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

KalVista Pharmaceuticals (KALV) Receivables - Other (2017)

KalVista Pharmaceuticals' Receivables - Other history spans 1 years, with the latest figure at $73000.0 for Q3 2017.

  • On a quarterly basis, Receivables - Other changed N/A to $73000.0 in Q3 2017 year-over-year; TTM through Jul 2017 was $73000.0, a N/A change, with the full-year FY2017 number at $297000.0, down 16.57% from a year prior.
  • Receivables - Other hit $73000.0 in Q3 2017 for KalVista Pharmaceuticals, down from $297000.0 in the prior quarter.
  • Over the last five years, Receivables - Other for KALV hit a ceiling of $398000.0 in Q1 2017 and a floor of $73000.0 in Q3 2017.